SlideShare a Scribd company logo
Corrective And Preventive
          Action
  CAPA: A Risk Mitigating Quality
             System



     Conducted by Gamal Amer, Ph.D.
                Principal
     Premier Compliance Services, Inc.




      © All rights reserved. Do not copy without permission.   1
FDA Initiative August 2002

  Pharmaceutical CGMP for the 21st Century:
          A Risk-based Approach

A science and risk-based approach to product quality regulation
       incorporating an integrated quality system approach




               © All rights reserved. Do not copy without permission.   2
Mitigating Risk
FDA Progress Reports discusses three
QA systems to mitigate risk:
1. Process Analytical Technology (PAT)
2. Corrective and Preventive Action (CAPA)
3. Quality by Design (QbD)



         © All rights reserved. Do not copy without permission.   3
Risk

       What Is Risk?
     What Causes It?
      Risk to Whom?
    Risk Manifestation?
        Risk Level?


© All rights reserved. Do not copy without permission.   4
Qu y ve s W c
Quality Events Which May Cause
                        y C use
         Increased Risk
• A problem occurs during clinical trials (patient
  complains/suffers)

• A deviation occurs during the manufacturing
• A piece of equipment fails while the process
      i    f     i      t f il hil th
  is engaged.
• Analytical result is not what was expected


                © All rights reserved. Do not copy without permission.   5
Events P t ti ll I
   E t Potentially Increasing
                          i
              Risk
   No negative q
        g      quality event occurred, but:
                     y
• Patient complaints show a negative trend.
• Operation drifting/trending towards action
         i d if i /      di        d     i
  limit.
• Analytical data trending towards
  unacceptable.
           © All rights reserved. Do not copy without permission.   6
These Events Pose:
•   Risk to the patient/public
•   Risk to the product
•   Risk to the personnel
•   Risk
    Ri k to the environement
             h      i
•   Risk to the company



             © All rights reserved. Do not copy without permission.   7
What Is Risk?

    The combination of the probability of
    occurrence of harm and the severity of that
    harm.*


*Guidance for Industry; ICH Q9 Quality Risk Management; June 2006




                       © All rights reserved. Do not copy without permission.   8
What Is The Risk?
• In Drug Application:
   – The pros and cons of the treatment
• In Process Design:
   – Failure to recognize source of variability and how CPP
     affect CQA of product
• In Process Qualification:
   – Failure to qualify a critical (high risk) portion of the
     process.
• In Manufacturing:
   – Quality events occurring as the process is engaged

               © All rights reserved. Do not copy without permission.   9
Some Sources of Increased Risk
       in Manufacturing?
• Processing Deviations and Non Conformance
• A ti Processing
  Aseptic P       i
• Labeling Errors (Majority of drug recalls due to
  mislabeling)
• Analytical and Measuring Errors
• D li with potent compounds
  Dealing ith t t              d
• People Errors

             © All rights reserved. Do not copy without permission.   10
Defining Level of Risk
Function of:
F    i    f
   – Severity
   –FFrequency
   – Detectability

• These three factors determine the numerical
  Risk Priority Number (RPN)
• Qualitative risk (low, medium, and high)

             © All rights reserved. Do not copy without permission.   11
CAPA = Corrective Action /
   Preventive Action




     © All rights reserved. Do not copy without permission.   12
Risk Within the Context of
          CAPA System
                   y
• A non-conformance or deviation occurs or a potential
  p
  problem is identified.
• These pose risk.
• CAPA should define the risk, its level, and means to
  mitigate it.
            it
• CAPA should then implement the actions to mitigate
  the risk and track to ensure closure.
• M i to ensure action is effective and did not
  Monitor                i i ff i         d
  introduced new risk(s).


             © All rights reserved. Do not copy without permission.   13
Non-conformance and Deviation
 Non-Conformance:
  Failure to meet a specified requirement.
                     p          q
 Deviation:
  Failure to follow or implement an established
  requirement. Typically this term is used
  relevant to processes (as in a “process
                                  process
  deviation”).


          © All rights reserved. Do not copy without permission.   14
Risk Level Factors: Severity

• What are the consequences of the non-conformance
                     q
  or deviation?
• How deleterious is that non-conformance or
  deviation to the consistent quality of the product?
• How high is the risk to the patient’s well being?



             © All rights reserved. Do not copy without permission.   15
Risk Level Factors: Frequency
• What are the probability of the reoccurrence
  of the non-conformance or deviation?
• Were attempts made to reduce such
  frequency and how effective?
• Review process history to determine.



           © All rights reserved. Do not copy without permission.   16
Risk Level Factors: Detectability

• What is the probability of the non-conformance or
  deviation b i d
  d i i being detected?   d?
• Can the effect/result of the non-conformance or
  deviation be dil
  d i ti b readily measured/seen?
                                d/    ?




            © All rights reserved. Do not copy without permission.   17
Change Control is an Important
    Component of CAPA



      © All rights reserved. Do not copy without permission.   18
Change Control: A Regulatory
          Imperative
          I       i
• Is a regulatory requirement
• 211.68(b) Appropriate controls shall be exercised
  over computer or related systems to assure that
            p                y
  changes....
• 211.100 (a) ....written procedures, including any
           ( )            p         ,         g y
  changes, shall be drafted, reviewed, and approved
  by the appropriate organizational units and
  reviewed and approved by the quality control unit.


            © All rights reserved. Do not copy without permission.   19
• 211 160( ) change in such specifications,
  211.160(a) h        i      h      ifi ti
  standards, sampling plans, test procedures, or
  other laboratory control mechanisms shall be
                            mechanisms,
  drafted by the appropriate organizational unit and
  reviewed and approved by the quality control unit.
• Guidance to Industry on Process Validation: The
  qualification plan for the facility and utilities
  should identify 1) studies.... 2)Criteria to assess
  outcome...It should also include the firm's
  requirements for the evaluation of changes.
       i      t f th        l ti      f h


            © All rights reserved. Do not copy without permission.   20
• ICH Q7-API GMP (13) A formal change control
  system should be established to evaluate all
  changes that could affect the production and
  control of the intermediate or API.
• A proposals f GMP relevant changes should
  Any           l for        l       h       h ld
  be drafted, reviewed, and approved by the
  appropriate organizational units and reviewed and
  approved by the quality unit(s).




            © All rights reserved. Do not copy without permission.   21
What is a Change Control
            System?
It is a formal system which is designed not to
 prevent change, but rather document and control it.
          change                                  it
 Its main purpose is to ensure that a
 system/process/operation is always in a GMP
  y       p         p              y
 compliant and validated state, regardless of changes
 made to it. It is usually implemented using a
 procedure.


           © All rights reserved. Do not copy without permission. 22   22
What is a Change Control
              System?
 ICH Q9 – Quality Risk Management
• T manage changes based on k
  To            h        b d knowledge and
                                      l d    d
  information accumulated in pharmaceutical
  development and during manufacturing
                             manufacturing.
• To evaluate the impact of the changes on the
  availability of the final product.



            © All rights reserved. Do not copy without permission. 23   23
What is a Change Control
              System?
• To evaluate the impact on product quality of
  changes to facility, equipment, material,
              facility equipment material
  manufacturing process or conducting technical
  transfers.
• To determine appropriate actions preceding the
  implementation of a change, e.g., additional testing,
  (re)qualification, (re)validation, communication
  with regulators.

             © All rights reserved. Do not copy without permission. 24   24
The Compliance/Validation
       p
       Life Cycle                     -




                               Compliant &
                             Validated System


Change Control
                            Implement Change
   System




                             Modified System



            © All rights reserved. Do not copy without permission. 25   25
Importance of Change Control
• Not to prevent change.
                 change
• To control and document change.
• Required by the regulations.
• Identify GMP and validation implications.
         y                        p
• Ascertain process remains in a state of
  control.
  control
• Must be implemented using a procedure.

          © All rights reserved. Do not copy without permission. 26   26
Change Control procedure
Change required




  Generate
Change Request




                   No
    GMP                       Implement Change
 Implications?                  Maintenance                End


          Yes


Requalification?   No        Implement Change
                                                            Issue GMP               Obtain Approval
 Revalidation?                 & Insure GMP
                             Requirements Done                Report

          Yes

     Requalify
                                  Obtain                     Change is
   Revalidate &                                                                        Change is
   Issue Reports                 Approvals                   Permanent                 Permanent


                                                                              End
                        © All rights reserved. Do not copy without permission. 27                     27
CAPA: Mitigating Risk
The degree of corrective and preventive
action taken to eliminate or minimize actual
or potential nonconformities must be
appropriate to the magnitude of the p
 pp p                 g             problem
and commensurate with the risks
encountered. (ICH Q )
              (   Q9)




         © All rights reserved. Do not copy without permission.   28
Risk Level and Appropriate Corrective Action

                       Risk Level
                       (RPN)                 Low              Medium         High
Corrective Action

No Further Investigation ,
No Corrective action
required

No Further Investigation
(Cause Evident),
Corrective action required

Further Investigation (Root
Cause Analysis), Corrective
            y ),
action required (Immediate;
e.g.. Recall), Prevent Cause



                    © All rights reserved. Do not copy without permission.          29
What Is CAPA?




© All rights reserved. Do not copy without permission.   30
CAPA Is:
• A quality based system
• Uses Non-conformance, Deviations and/or an
  Expectation of such as input
• Uses many of the quality systems in place as tools:
   –   Historical Quality Issues and Audit Reports
   –   Environmental and Process Monitoring Data
   –   Product Complaints
   –   Equipment Service & Maintenance Records
   –   Process and scientific Knowledge
   –   Operating Procedures and Methodology


                 © All rights reserved. Do not copy without permission.   31
CAPA Uses:
• Policies and procedures to in estigate
               proced res investigate
  quality problems.
• Policies and procedures to identify and
  implement corrective and preventive
  actions.
  actions
• A tracking mechanism to ensure
  investigation and proper corrective actions
  are conducted and implemented on a timely
  basis.
           © All rights reserved. Do not copy without permission.   32
CAPA Investigation
• Investigate the cause of non-conformity or
  deviation as it relates to the product, processes,
  and the quality system. (reactive)
• I
  Investigate potential risk of an expected or
        ti t     t ti l i k f            t d
  anticipated event. (proactive)
• Depending on risk severity the investigation may
                      severity,
  need to define the “Root Cause.”
• Use tools such as HAZOP, HACCP, Failure Mode
                              ,        ,
  & Effect Analysis, Fault Tree Analysis, What If,
  etc.
            © All rights reserved. Do not copy without permission.   33
CAPA Identification
• Identify the action needed to correct, reduce, or
  p
  prevent recurrence of nonconformance of product
                                             p
  and other quality problems.
• Identify the action needed to correct and prevent
  recurrence of the deviation in the process.
• Identify the action needed to prevent the potential
  occurrence of an anticipated quality event.

               © All rights reserved. Do not copy without permission.   34
Possible Corrective Actions
• Design Changes*
• Manufacturing Process Changes*
• Removal of product from the market through
  recall
• Operator Training
• Labeling changes*
• Patient education
   ________________________________________________________________________________
* Keep in mind that making changes must be managed using change control in order to
  avoid introducing additional risk.


                    © All rights reserved. Do not copy without permission.            35
Tracking CAPA Activities
• What to track?
   – The quality event and timing for initiating an investigation
   – Timing for completing assessment
   – Timing for developing action plan
   – Timing for implementing all necessary actions (changes,
     training, document modification, etc.)
   – Timing for completing the necessary documentation
   – Completion of the actions and closure of the deviation or
     nonconformance

               © All rights reserved. Do not copy without permission.   36
Tracking CAPA Activities
• How to track?
  – Manual Tracking
     • Too much paper
     • Very cumbersome and time consuming
     • Limited Access
  – Software Packages (Part 11 compliant)
     • Trackwise (MS Outlook)
     • Livelink (Lotus)

           © All rights reserved. Do not copy without permission.   37
Post CAPA Monitoring
• Ensures actions were effective in mitigating
  the risk.
• Ensure actions were effective in
  correcting/preventive the problem.
• Ensures no additional risks were introduced
  due to the actions taken.
• Required as part of GMP compliance and
  process validation (FDA Guidance 1/2011).
           © All rights reserved. Do not copy without permission.   38
Typical CAPA Overall Approach
  Quality Event



   History            Identify Risk                     Risk
                                                        Ri k
                                                        Acceptance                       Document
 Monitoring


Complaints                                                                                 Track&
                      Analyze Risk                      Risk Reduction                     Monitor
 Science &
 Knowledge

Procedures, Service
                                                         Risk                          Communicate
& Maintenance          Evaluate Risk                     Elimination/
                       Assign
                       A i RPN                           prevention
                                                                                       Review
     Risk
     Assessment/
                                        Identify &                           Document, Track,
     Investigate
                                                                             Monitor &
                                        Implement Actions
                                            l      A i                       Communicate
                             © All rights reserved. Do not copy without permission.                  39
System Components
• D i ti reporting and i
  Deviation      ti    d investigation procedure.
                                ti ti        d
• Rework Procedures.
• M i
  Maintenance records, hi
                    d historical Data, quality audit
                              i lD        li     di
  results, etc.
• P
  Process and environmental monitoring programs.
              d   i       t l     it i
• Change Control Procedure.
• Ri k Analysis Procedures such as HAZOP,
  Risk A l i P       d          h HAZOP
  HACCP, Fault Tree Analysis, etc.

            © All rights reserved. Do not copy without permission.   40
CAPA
Steps to Be Taken




© All rights reserved. Do not copy without permission.   41
Label and Segregate Non-
       conforming Product
• Ensure nonconforming product is properly
  labeled (for example, HOLD, REJECT,
               example HOLD REJECT
  QUARANTINE).
• E
  Ensure suspect or non-conforming product
                 t           f   i      d t
  is properly labeled and segregated (not
  used) t prevent further use pending
      d) to        t f th         di
  disposition.

          © All rights reserved. Do not copy without permission.   42
Document The Issue
• Record nonconformance on a
  Nonconforming Materials Report.
                 g              p
• Record Deviation on a Deviation Reporting
  Form.
  Form
• Document all studies and decisions made
  during the investigation of the quality event.
                                          event


           © All rights reserved. Do not copy without permission.   43
Segregate Material & Equipment
• A
  Assure that suspect materials (non-product) i
           h                  i l (        d ) is
  segregated and labeled.
• Assure all suspect lots batches units, materials
                      lots, batches, units materials,
  etc are identified and segregated.
• Assure that the segregation (who, what, where,
                     g g        (     ,    ,       ,
  when, how) is documented on the
  nonconformance report.
• T and lock all equipment and parts of the
  Tag d l k ll          i          d       f h
  process which maybe suspect.

             © All rights reserved. Do not copy without permission.   44
Evaluate
• Review the event, the circumstances surrounding the event.
• Document relevant details as part of the nonconformance
  or deviation report.
               report
• Risk to quality should be linked to protecting the patient.
• Use RPN to help determine need for in-depth investigation
  and Corrective/Preventive Action (in other words: the
  effort, formality and documentation should be
  commensurate with the level of risk and be based on
  science*).
__________________________________________________________________________
*Guidance for Industry; ICH Q9 Quality Risk Management; June 2006



                           © All rights reserved. Do not copy without permission.   45
Risk Level and Appropriate Corrective Action

                       Risk Level
                       (RPN)                 Low              Medium         High
Corrective Action

Further Investigation (Root
Cause Analysis), Corrective
action required (Immediate;
e.g.. Re ll) P e e t C e
e Recall), Prevent Cause

No Further Investigation
(Cause Evident),
Corrective action required


No Further Investigation , No
Corrective action required




                    © All rights reserved. Do not copy without permission.          46
Take Action
• M k necessary changes to reduce risk or
  Make               h           d      ik
  eliminate it.
• Invoke Change Control.
                   Control
• Track to ensure CAPA closure in a timely fashion.
• Evaluate the actions to ensure they were effective
  in mitigating the risk as intended.
• Monitor the process to ensure it has not been
                p
  negatively affected by changes and that no
  additional or different risks were introduced.

            © All rights reserved. Do not copy without permission.   47
Benefits of a Robust CAPA
              System
• Fulfills the promise of continuous improvement
• Leads to better customer satisfaction and less risk
  to the public.
      h     bli
• Better use of resources through a structured QA
  system.
  system
• Facilitate better and more informed decisions by
  manufacturers.
• Makes good business and financial sense.
• Increasing your compliance q
             gy         p      quotient.
             © All rights reserved. Do not copy without permission.   48
Summary
                                 y
• CAPA is a regulatory requirement which makes business sense.
• CAPA is a risk mitigating approach, which fulfills the promise of
  continuous improvement
              improvement.
• Non-conformances, deviations or anticipated quality events are
  input to the CAPA program.
• All aspects of the CAPA program should be thoroughly
  documented.
• Risk level assessment, as part of CAPA:
         p
         provides the means for rationalizing the scope and
                                             g        p
         extent of investigation and/or corrective action
         necessary.
         helps management assign resources to tasks providing
         the most value and having the biggest impact on
                    al e     ha ing
         quality and customer satisfaction.
• Tracking, reviewing, and monitoring CAPA related activities is an
  important aspect of the program.

               © All rights reserved. Do not copy without permission.   49

More Related Content

What's hot

Corrective and Preventive action (CAPA)
Corrective and Preventive action (CAPA)Corrective and Preventive action (CAPA)
Corrective and Preventive action (CAPA)
Krishnan Lakshmi Narayanan
 
4. capa industry basics - final
4. capa   industry basics - final4. capa   industry basics - final
4. capa industry basics - final
Tetali RadhaKrishna
 
Corrective & Preventive actions (CAPA)
Corrective & Preventive actions (CAPA)Corrective & Preventive actions (CAPA)
Corrective & Preventive actions (CAPA)
Yash Menghani
 
GMP Training: Handling of deviation
GMP Training: Handling of deviationGMP Training: Handling of deviation
GMP Training: Handling of deviation
Dr. Amsavel A
 
Root cause analysis
Root cause analysisRoot cause analysis
Root cause analysis
Krishnan Lakshmi Narayanan
 
GMP- APQR training
GMP- APQR  trainingGMP- APQR  training
GMP- APQR training
Amsavel Vel
 
CAPA, Root Cause Analysis and Risk Management
CAPA, Root Cause Analysis and Risk ManagementCAPA, Root Cause Analysis and Risk Management
CAPA, Root Cause Analysis and Risk ManagementJoseph Tarsio
 
Product quality review
Product quality reviewProduct quality review
Gmp change control by amsavel
Gmp  change control  by amsavelGmp  change control  by amsavel
Gmp change control by amsavel
Amsavel Vel
 
Overview on “Computer System Validation” CSV
Overview on  “Computer System Validation” CSVOverview on  “Computer System Validation” CSV
Overview on “Computer System Validation” CSV
Anil Sharma
 
Gamp Riskbased Approch To Validation
Gamp Riskbased Approch To ValidationGamp Riskbased Approch To Validation
Gamp Riskbased Approch To Validation
Rajendra Sadare
 
Risk management using FMEA in pharma
Risk management using FMEA in pharmaRisk management using FMEA in pharma
Risk management using FMEA in pharma
Sandeep Naik
 
CAPA
CAPACAPA
Deviation and root cause analysis in Pharma
Deviation and root cause analysis in PharmaDeviation and root cause analysis in Pharma
Deviation and root cause analysis in Pharma
Subhash Sanghani
 
ICH Q9 Quality Risk Management
ICH Q9 Quality Risk ManagementICH Q9 Quality Risk Management
ICH Q9 Quality Risk Management
Seetharam Kandarpa ASQ CMQ/OE, CPGP, CQA
 
Qms ISO 13485 2016 short overview
Qms ISO 13485 2016 short overview Qms ISO 13485 2016 short overview
Qms ISO 13485 2016 short overview
RohitParkale
 
Root Cause Analysis - How It Informs CAPA
Root Cause Analysis - How It Informs CAPARoot Cause Analysis - How It Informs CAPA
Root Cause Analysis - How It Informs CAPA
SafetyChain Software
 
Change management system
Change management systemChange management system
Change management system
manusb07
 
Corrective and preventive action
Corrective  and preventive actionCorrective  and preventive action
Corrective and preventive action
SnehaGhadigaonkar
 

What's hot (20)

Corrective and Preventive action (CAPA)
Corrective and Preventive action (CAPA)Corrective and Preventive action (CAPA)
Corrective and Preventive action (CAPA)
 
4. capa industry basics - final
4. capa   industry basics - final4. capa   industry basics - final
4. capa industry basics - final
 
Presentation on QRM_NS
Presentation on QRM_NSPresentation on QRM_NS
Presentation on QRM_NS
 
Corrective & Preventive actions (CAPA)
Corrective & Preventive actions (CAPA)Corrective & Preventive actions (CAPA)
Corrective & Preventive actions (CAPA)
 
GMP Training: Handling of deviation
GMP Training: Handling of deviationGMP Training: Handling of deviation
GMP Training: Handling of deviation
 
Root cause analysis
Root cause analysisRoot cause analysis
Root cause analysis
 
GMP- APQR training
GMP- APQR  trainingGMP- APQR  training
GMP- APQR training
 
CAPA, Root Cause Analysis and Risk Management
CAPA, Root Cause Analysis and Risk ManagementCAPA, Root Cause Analysis and Risk Management
CAPA, Root Cause Analysis and Risk Management
 
Product quality review
Product quality reviewProduct quality review
Product quality review
 
Gmp change control by amsavel
Gmp  change control  by amsavelGmp  change control  by amsavel
Gmp change control by amsavel
 
Overview on “Computer System Validation” CSV
Overview on  “Computer System Validation” CSVOverview on  “Computer System Validation” CSV
Overview on “Computer System Validation” CSV
 
Gamp Riskbased Approch To Validation
Gamp Riskbased Approch To ValidationGamp Riskbased Approch To Validation
Gamp Riskbased Approch To Validation
 
Risk management using FMEA in pharma
Risk management using FMEA in pharmaRisk management using FMEA in pharma
Risk management using FMEA in pharma
 
CAPA
CAPACAPA
CAPA
 
Deviation and root cause analysis in Pharma
Deviation and root cause analysis in PharmaDeviation and root cause analysis in Pharma
Deviation and root cause analysis in Pharma
 
ICH Q9 Quality Risk Management
ICH Q9 Quality Risk ManagementICH Q9 Quality Risk Management
ICH Q9 Quality Risk Management
 
Qms ISO 13485 2016 short overview
Qms ISO 13485 2016 short overview Qms ISO 13485 2016 short overview
Qms ISO 13485 2016 short overview
 
Root Cause Analysis - How It Informs CAPA
Root Cause Analysis - How It Informs CAPARoot Cause Analysis - How It Informs CAPA
Root Cause Analysis - How It Informs CAPA
 
Change management system
Change management systemChange management system
Change management system
 
Corrective and preventive action
Corrective  and preventive actionCorrective  and preventive action
Corrective and preventive action
 

Viewers also liked

Corrective and preventive action plan CAPA report form
Corrective and preventive action plan  CAPA report formCorrective and preventive action plan  CAPA report form
Corrective and preventive action plan CAPA report form
Connie Dello Buono
 
Capa A Five Step Action Plan
Capa   A Five Step Action PlanCapa   A Five Step Action Plan
Capa A Five Step Action PlanDigital-360
 
CAPA Training Presentation
CAPA Training PresentationCAPA Training Presentation
CAPA Training Presentation
Nancy Watts
 
Root Cause Corrective Action
Root Cause Corrective ActionRoot Cause Corrective Action
Root Cause Corrective Action
Ubersoldat
 
Pharmaceutical Deviation SOP
Pharmaceutical Deviation SOPPharmaceutical Deviation SOP
Pharmaceutical Deviation SOPMohamed Wallash
 
Quality Risk management Application of FMEA
Quality Risk management  Application of FMEAQuality Risk management  Application of FMEA
Quality Risk management Application of FMEA
GMP EDUCATION : Not for Profit Organization
 
Shift Left - Approach and practices with IBM
Shift Left - Approach and practices with IBMShift Left - Approach and practices with IBM
Shift Left - Approach and practices with IBM
IBM UrbanCode Products
 
Supply Chain Risk Management
Supply Chain Risk ManagementSupply Chain Risk Management
Supply Chain Risk Management
Anand Subramaniam
 
Customer Complaint Management
Customer Complaint ManagementCustomer Complaint Management
Customer Complaint Management
Faakor Agyekum
 
Risk Management Framework
Risk Management FrameworkRisk Management Framework
Risk Management Framework
Anand Subramaniam
 
Capa The Challenge And Solution
Capa The Challenge And SolutionCapa The Challenge And Solution
Capa The Challenge And Solution
antonygamal
 
Creating the Case for Enterprise Quality
Creating the Case for Enterprise QualityCreating the Case for Enterprise Quality
Creating the Case for Enterprise Quality
Sparta Systems
 
Effective Use of CAPA in Remediating Quality Management Systems
Effective Use of CAPA in Remediating Quality Management SystemsEffective Use of CAPA in Remediating Quality Management Systems
Effective Use of CAPA in Remediating Quality Management Systems
Maetrics
 
The FDA Guidance of a Risk-Based Approach to Monitoring as Viewed By CDM
The FDA Guidance of a Risk-Based Approach to Monitoring as Viewed By CDMThe FDA Guidance of a Risk-Based Approach to Monitoring as Viewed By CDM
The FDA Guidance of a Risk-Based Approach to Monitoring as Viewed By CDM
www.datatrak.com
 
Risk and Response-APMP 2011-Brenda Crist 6-2-11
Risk and Response-APMP 2011-Brenda Crist 6-2-11Risk and Response-APMP 2011-Brenda Crist 6-2-11
Risk and Response-APMP 2011-Brenda Crist 6-2-11
Lohfeld Consulting Group
 
David's Great Room
David's Great RoomDavid's Great Room
David's Great Room
Akberet Hadgu
 
Quality management system
Quality management systemQuality management system
Quality management systempareshpanshikar
 
Corretive & Preventive Action (CAPA) 101
Corretive & Preventive Action (CAPA) 101Corretive & Preventive Action (CAPA) 101
Corretive & Preventive Action (CAPA) 101jscover
 
SALMON, Wesley-Logica.
SALMON, Wesley-Logica.SALMON, Wesley-Logica.
SALMON, Wesley-Logica.unirio2011
 

Viewers also liked (20)

Corrective and preventive action plan CAPA report form
Corrective and preventive action plan  CAPA report formCorrective and preventive action plan  CAPA report form
Corrective and preventive action plan CAPA report form
 
Corrective action
Corrective actionCorrective action
Corrective action
 
Capa A Five Step Action Plan
Capa   A Five Step Action PlanCapa   A Five Step Action Plan
Capa A Five Step Action Plan
 
CAPA Training Presentation
CAPA Training PresentationCAPA Training Presentation
CAPA Training Presentation
 
Root Cause Corrective Action
Root Cause Corrective ActionRoot Cause Corrective Action
Root Cause Corrective Action
 
Pharmaceutical Deviation SOP
Pharmaceutical Deviation SOPPharmaceutical Deviation SOP
Pharmaceutical Deviation SOP
 
Quality Risk management Application of FMEA
Quality Risk management  Application of FMEAQuality Risk management  Application of FMEA
Quality Risk management Application of FMEA
 
Shift Left - Approach and practices with IBM
Shift Left - Approach and practices with IBMShift Left - Approach and practices with IBM
Shift Left - Approach and practices with IBM
 
Supply Chain Risk Management
Supply Chain Risk ManagementSupply Chain Risk Management
Supply Chain Risk Management
 
Customer Complaint Management
Customer Complaint ManagementCustomer Complaint Management
Customer Complaint Management
 
Risk Management Framework
Risk Management FrameworkRisk Management Framework
Risk Management Framework
 
Capa The Challenge And Solution
Capa The Challenge And SolutionCapa The Challenge And Solution
Capa The Challenge And Solution
 
Creating the Case for Enterprise Quality
Creating the Case for Enterprise QualityCreating the Case for Enterprise Quality
Creating the Case for Enterprise Quality
 
Effective Use of CAPA in Remediating Quality Management Systems
Effective Use of CAPA in Remediating Quality Management SystemsEffective Use of CAPA in Remediating Quality Management Systems
Effective Use of CAPA in Remediating Quality Management Systems
 
The FDA Guidance of a Risk-Based Approach to Monitoring as Viewed By CDM
The FDA Guidance of a Risk-Based Approach to Monitoring as Viewed By CDMThe FDA Guidance of a Risk-Based Approach to Monitoring as Viewed By CDM
The FDA Guidance of a Risk-Based Approach to Monitoring as Viewed By CDM
 
Risk and Response-APMP 2011-Brenda Crist 6-2-11
Risk and Response-APMP 2011-Brenda Crist 6-2-11Risk and Response-APMP 2011-Brenda Crist 6-2-11
Risk and Response-APMP 2011-Brenda Crist 6-2-11
 
David's Great Room
David's Great RoomDavid's Great Room
David's Great Room
 
Quality management system
Quality management systemQuality management system
Quality management system
 
Corretive & Preventive Action (CAPA) 101
Corretive & Preventive Action (CAPA) 101Corretive & Preventive Action (CAPA) 101
Corretive & Preventive Action (CAPA) 101
 
SALMON, Wesley-Logica.
SALMON, Wesley-Logica.SALMON, Wesley-Logica.
SALMON, Wesley-Logica.
 

Similar to CAPA: A Risk Mitigating Quality System

Amergamalpres1 130129172315-phpapp01
Amergamalpres1 130129172315-phpapp01Amergamalpres1 130129172315-phpapp01
Amergamalpres1 130129172315-phpapp01
Fasika Alemu
 
TPM: Quality Maintenance (Hinshitsu Hozen)
TPM: Quality Maintenance (Hinshitsu Hozen)TPM: Quality Maintenance (Hinshitsu Hozen)
TPM: Quality Maintenance (Hinshitsu Hozen)
Operational Excellence Consulting
 
Quality_in_the_Coag_Lab_082819.pdf
Quality_in_the_Coag_Lab_082819.pdfQuality_in_the_Coag_Lab_082819.pdf
Quality_in_the_Coag_Lab_082819.pdf
SubhaShree852628
 
App. Of Stat. Tools
App. Of Stat. ToolsApp. Of Stat. Tools
App. Of Stat. ToolsDenny Thayil
 
Control charts in statistical quality control
Control charts in statistical quality controlControl charts in statistical quality control
Control charts in statistical quality control
rakheechhibber1971
 
Apply Risk Management to Computerized and Automated Systems
Apply Risk Management to Computerized and Automated SystemsApply Risk Management to Computerized and Automated Systems
Apply Risk Management to Computerized and Automated Systems
Institute of Validation Technology
 
GOOD ENGINEERING PRACTICES
GOOD ENGINEERING PRACTICESGOOD ENGINEERING PRACTICES
GOOD ENGINEERING PRACTICES
Aditya Singh
 
BMT GxP Training 10-22-2021 1.pptx
BMT GxP Training 10-22-2021 1.pptxBMT GxP Training 10-22-2021 1.pptx
BMT GxP Training 10-22-2021 1.pptx
haploidentical
 
Focus on FDA cGMPs inspections
Focus on FDA cGMPs inspections Focus on FDA cGMPs inspections
Focus on FDA cGMPs inspections
JinalPrajapati13
 
PHARMACEUTICAL PROCESS VALIDATION CURRENT REGULATORY ASPECTS
PHARMACEUTICAL PROCESS VALIDATION CURRENT REGULATORY ASPECTSPHARMACEUTICAL PROCESS VALIDATION CURRENT REGULATORY ASPECTS
PHARMACEUTICAL PROCESS VALIDATION CURRENT REGULATORY ASPECTS
Md. Saddam Nawaz
 
Overview of Computerized Systems Compliance Using the GAMP® 5 Guide
Overview of Computerized Systems Compliance Using the GAMP® 5 GuideOverview of Computerized Systems Compliance Using the GAMP® 5 Guide
Overview of Computerized Systems Compliance Using the GAMP® 5 Guide
ProPharma Group
 
Six sigma and pharmaceutical industry4
Six sigma and pharmaceutical industry4Six sigma and pharmaceutical industry4
Six sigma and pharmaceutical industry4DrAbdulaziz Saddique
 
ICH Q 10 guidline
ICH Q 10 guidline  ICH Q 10 guidline
ICH Q 10 guidline
umeshlove4u
 
Application of Quality Risk Management in Commissioning & Qualifcation
Application of Quality Risk Management in Commissioning & QualifcationApplication of Quality Risk Management in Commissioning & Qualifcation
Application of Quality Risk Management in Commissioning & Qualifcation
GMP EDUCATION : Not for Profit Organization
 
Risk minor major critical
Risk minor major criticalRisk minor major critical
Risk minor major criticalyasser mekky
 

Similar to CAPA: A Risk Mitigating Quality System (20)

Amergamalpres1 130129172315-phpapp01
Amergamalpres1 130129172315-phpapp01Amergamalpres1 130129172315-phpapp01
Amergamalpres1 130129172315-phpapp01
 
Implementing Risk Management
Implementing Risk ManagementImplementing Risk Management
Implementing Risk Management
 
Implementing risk management
Implementing risk managementImplementing risk management
Implementing risk management
 
Quality facilities hvac and water systems
Quality facilities hvac and water systemsQuality facilities hvac and water systems
Quality facilities hvac and water systems
 
Quality Facilities HVAC and Water Systems
Quality Facilities HVAC and Water SystemsQuality Facilities HVAC and Water Systems
Quality Facilities HVAC and Water Systems
 
TPM: Quality Maintenance (Hinshitsu Hozen)
TPM: Quality Maintenance (Hinshitsu Hozen)TPM: Quality Maintenance (Hinshitsu Hozen)
TPM: Quality Maintenance (Hinshitsu Hozen)
 
Quality_in_the_Coag_Lab_082819.pdf
Quality_in_the_Coag_Lab_082819.pdfQuality_in_the_Coag_Lab_082819.pdf
Quality_in_the_Coag_Lab_082819.pdf
 
App. Of Stat. Tools
App. Of Stat. ToolsApp. Of Stat. Tools
App. Of Stat. Tools
 
Control charts in statistical quality control
Control charts in statistical quality controlControl charts in statistical quality control
Control charts in statistical quality control
 
Apply Risk Management to Computerized and Automated Systems
Apply Risk Management to Computerized and Automated SystemsApply Risk Management to Computerized and Automated Systems
Apply Risk Management to Computerized and Automated Systems
 
GOOD ENGINEERING PRACTICES
GOOD ENGINEERING PRACTICESGOOD ENGINEERING PRACTICES
GOOD ENGINEERING PRACTICES
 
BMT GxP Training 10-22-2021 1.pptx
BMT GxP Training 10-22-2021 1.pptxBMT GxP Training 10-22-2021 1.pptx
BMT GxP Training 10-22-2021 1.pptx
 
Focus on FDA cGMPs inspections
Focus on FDA cGMPs inspections Focus on FDA cGMPs inspections
Focus on FDA cGMPs inspections
 
PHARMACEUTICAL PROCESS VALIDATION CURRENT REGULATORY ASPECTS
PHARMACEUTICAL PROCESS VALIDATION CURRENT REGULATORY ASPECTSPHARMACEUTICAL PROCESS VALIDATION CURRENT REGULATORY ASPECTS
PHARMACEUTICAL PROCESS VALIDATION CURRENT REGULATORY ASPECTS
 
Overview of Computerized Systems Compliance Using the GAMP® 5 Guide
Overview of Computerized Systems Compliance Using the GAMP® 5 GuideOverview of Computerized Systems Compliance Using the GAMP® 5 Guide
Overview of Computerized Systems Compliance Using the GAMP® 5 Guide
 
Six sigma and pharmaceutical industry4
Six sigma and pharmaceutical industry4Six sigma and pharmaceutical industry4
Six sigma and pharmaceutical industry4
 
ICH Q 10 guidline
ICH Q 10 guidline  ICH Q 10 guidline
ICH Q 10 guidline
 
160702-JC-Auditing
160702-JC-Auditing160702-JC-Auditing
160702-JC-Auditing
 
Application of Quality Risk Management in Commissioning & Qualifcation
Application of Quality Risk Management in Commissioning & QualifcationApplication of Quality Risk Management in Commissioning & Qualifcation
Application of Quality Risk Management in Commissioning & Qualifcation
 
Risk minor major critical
Risk minor major criticalRisk minor major critical
Risk minor major critical
 

More from Institute of Validation Technology

Incorporate Domestic and International Regulations for Effective GMP Auditing
Incorporate Domestic and International Regulations for Effective GMP AuditingIncorporate Domestic and International Regulations for Effective GMP Auditing
Incorporate Domestic and International Regulations for Effective GMP Auditing
Institute of Validation Technology
 
Notification Tactics for Improved Notification Tactics For Improved Field Act...
Notification Tactics for Improved Notification Tactics For Improved Field Act...Notification Tactics for Improved Notification Tactics For Improved Field Act...
Notification Tactics for Improved Notification Tactics For Improved Field Act...
Institute of Validation Technology
 
Lifecycle Approach to Cleaning Validation
Lifecycle Approach to Cleaning ValidationLifecycle Approach to Cleaning Validation
Lifecycle Approach to Cleaning Validation
Institute of Validation Technology
 
Computer System Validation Then and Now — Learning Management in the Cloud
Computer System Validation Then and Now — Learning Management in the CloudComputer System Validation Then and Now — Learning Management in the Cloud
Computer System Validation Then and Now — Learning Management in the Cloud
Institute of Validation Technology
 
Applying QbD to Biotech Process Validation
Applying QbD to Biotech Process ValidationApplying QbD to Biotech Process Validation
Applying QbD to Biotech Process Validation
Institute of Validation Technology
 
Management Strategies to Facilitate Continual Quality Improvement
Management Strategies to Facilitate Continual Quality ImprovementManagement Strategies to Facilitate Continual Quality Improvement
Management Strategies to Facilitate Continual Quality Improvement
Institute of Validation Technology
 
Understand the Evolving Regulations for Aseptic Cleaning and Environmental Mo...
Understand the Evolving Regulations for Aseptic Cleaning and Environmental Mo...Understand the Evolving Regulations for Aseptic Cleaning and Environmental Mo...
Understand the Evolving Regulations for Aseptic Cleaning and Environmental Mo...
Institute of Validation Technology
 
Effective Use of Environmental Monitoring Data Trending
Effective Use of Environmental Monitoring Data TrendingEffective Use of Environmental Monitoring Data Trending
Effective Use of Environmental Monitoring Data Trending
Institute of Validation Technology
 
Mock Inspection Case Studies
Mock Inspection Case StudiesMock Inspection Case Studies
Mock Inspection Case Studies
Institute of Validation Technology
 
Validation Master Plan
Validation Master PlanValidation Master Plan
Validation Master Plan
Institute of Validation Technology
 
Designing Stability Studies for Early Stages of Pharmaceutical Development
Designing Stability Studies for Early Stages of Pharmaceutical DevelopmentDesigning Stability Studies for Early Stages of Pharmaceutical Development
Designing Stability Studies for Early Stages of Pharmaceutical Development
Institute of Validation Technology
 
Determine Exceptions to Validation
Determine Exceptions to ValidationDetermine Exceptions to Validation
Determine Exceptions to Validation
Institute of Validation Technology
 
Conduct a Gap Analysis of a Validation Programme
Conduct a Gap Analysis of a Validation ProgrammeConduct a Gap Analysis of a Validation Programme
Conduct a Gap Analysis of a Validation Programme
Institute of Validation Technology
 
FDA Inspection
FDA InspectionFDA Inspection
Incorporate CPV and Continual Improvement into your Validation Plan
Incorporate CPV and Continual Improvement into your Validation PlanIncorporate CPV and Continual Improvement into your Validation Plan
Incorporate CPV and Continual Improvement into your Validation Plan
Institute of Validation Technology
 
Compliance by Design and Compliance Master Plan
Compliance by Design and Compliance Master PlanCompliance by Design and Compliance Master Plan
Compliance by Design and Compliance Master Plan
Institute of Validation Technology
 
Introduction to Statistical Applications for Process Validation
Introduction to Statistical Applications for Process ValidationIntroduction to Statistical Applications for Process Validation
Introduction to Statistical Applications for Process Validation
Institute of Validation Technology
 
Risk-Based Approaches in GMP’s Project Life Cycles
Risk-Based Approaches in GMP’s Project Life CyclesRisk-Based Approaches in GMP’s Project Life Cycles
Risk-Based Approaches in GMP’s Project Life Cycles
Institute of Validation Technology
 
GMP Systems Integration–Combine Results and Utilize as a Compliance Tool
GMP Systems Integration–Combine Results and Utilize as a Compliance ToolGMP Systems Integration–Combine Results and Utilize as a Compliance Tool
GMP Systems Integration–Combine Results and Utilize as a Compliance Tool
Institute of Validation Technology
 
A Lifecycle Approach to Process Validation
A Lifecycle Approach to Process ValidationA Lifecycle Approach to Process Validation
A Lifecycle Approach to Process Validation
Institute of Validation Technology
 

More from Institute of Validation Technology (20)

Incorporate Domestic and International Regulations for Effective GMP Auditing
Incorporate Domestic and International Regulations for Effective GMP AuditingIncorporate Domestic and International Regulations for Effective GMP Auditing
Incorporate Domestic and International Regulations for Effective GMP Auditing
 
Notification Tactics for Improved Notification Tactics For Improved Field Act...
Notification Tactics for Improved Notification Tactics For Improved Field Act...Notification Tactics for Improved Notification Tactics For Improved Field Act...
Notification Tactics for Improved Notification Tactics For Improved Field Act...
 
Lifecycle Approach to Cleaning Validation
Lifecycle Approach to Cleaning ValidationLifecycle Approach to Cleaning Validation
Lifecycle Approach to Cleaning Validation
 
Computer System Validation Then and Now — Learning Management in the Cloud
Computer System Validation Then and Now — Learning Management in the CloudComputer System Validation Then and Now — Learning Management in the Cloud
Computer System Validation Then and Now — Learning Management in the Cloud
 
Applying QbD to Biotech Process Validation
Applying QbD to Biotech Process ValidationApplying QbD to Biotech Process Validation
Applying QbD to Biotech Process Validation
 
Management Strategies to Facilitate Continual Quality Improvement
Management Strategies to Facilitate Continual Quality ImprovementManagement Strategies to Facilitate Continual Quality Improvement
Management Strategies to Facilitate Continual Quality Improvement
 
Understand the Evolving Regulations for Aseptic Cleaning and Environmental Mo...
Understand the Evolving Regulations for Aseptic Cleaning and Environmental Mo...Understand the Evolving Regulations for Aseptic Cleaning and Environmental Mo...
Understand the Evolving Regulations for Aseptic Cleaning and Environmental Mo...
 
Effective Use of Environmental Monitoring Data Trending
Effective Use of Environmental Monitoring Data TrendingEffective Use of Environmental Monitoring Data Trending
Effective Use of Environmental Monitoring Data Trending
 
Mock Inspection Case Studies
Mock Inspection Case StudiesMock Inspection Case Studies
Mock Inspection Case Studies
 
Validation Master Plan
Validation Master PlanValidation Master Plan
Validation Master Plan
 
Designing Stability Studies for Early Stages of Pharmaceutical Development
Designing Stability Studies for Early Stages of Pharmaceutical DevelopmentDesigning Stability Studies for Early Stages of Pharmaceutical Development
Designing Stability Studies for Early Stages of Pharmaceutical Development
 
Determine Exceptions to Validation
Determine Exceptions to ValidationDetermine Exceptions to Validation
Determine Exceptions to Validation
 
Conduct a Gap Analysis of a Validation Programme
Conduct a Gap Analysis of a Validation ProgrammeConduct a Gap Analysis of a Validation Programme
Conduct a Gap Analysis of a Validation Programme
 
FDA Inspection
FDA InspectionFDA Inspection
FDA Inspection
 
Incorporate CPV and Continual Improvement into your Validation Plan
Incorporate CPV and Continual Improvement into your Validation PlanIncorporate CPV and Continual Improvement into your Validation Plan
Incorporate CPV and Continual Improvement into your Validation Plan
 
Compliance by Design and Compliance Master Plan
Compliance by Design and Compliance Master PlanCompliance by Design and Compliance Master Plan
Compliance by Design and Compliance Master Plan
 
Introduction to Statistical Applications for Process Validation
Introduction to Statistical Applications for Process ValidationIntroduction to Statistical Applications for Process Validation
Introduction to Statistical Applications for Process Validation
 
Risk-Based Approaches in GMP’s Project Life Cycles
Risk-Based Approaches in GMP’s Project Life CyclesRisk-Based Approaches in GMP’s Project Life Cycles
Risk-Based Approaches in GMP’s Project Life Cycles
 
GMP Systems Integration–Combine Results and Utilize as a Compliance Tool
GMP Systems Integration–Combine Results and Utilize as a Compliance ToolGMP Systems Integration–Combine Results and Utilize as a Compliance Tool
GMP Systems Integration–Combine Results and Utilize as a Compliance Tool
 
A Lifecycle Approach to Process Validation
A Lifecycle Approach to Process ValidationA Lifecycle Approach to Process Validation
A Lifecycle Approach to Process Validation
 

Recently uploaded

ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 

Recently uploaded (20)

ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 

CAPA: A Risk Mitigating Quality System

  • 1. Corrective And Preventive Action CAPA: A Risk Mitigating Quality System Conducted by Gamal Amer, Ph.D. Principal Premier Compliance Services, Inc. © All rights reserved. Do not copy without permission. 1
  • 2. FDA Initiative August 2002 Pharmaceutical CGMP for the 21st Century: A Risk-based Approach A science and risk-based approach to product quality regulation incorporating an integrated quality system approach © All rights reserved. Do not copy without permission. 2
  • 3. Mitigating Risk FDA Progress Reports discusses three QA systems to mitigate risk: 1. Process Analytical Technology (PAT) 2. Corrective and Preventive Action (CAPA) 3. Quality by Design (QbD) © All rights reserved. Do not copy without permission. 3
  • 4. Risk What Is Risk? What Causes It? Risk to Whom? Risk Manifestation? Risk Level? © All rights reserved. Do not copy without permission. 4
  • 5. Qu y ve s W c Quality Events Which May Cause y C use Increased Risk • A problem occurs during clinical trials (patient complains/suffers) • A deviation occurs during the manufacturing • A piece of equipment fails while the process i f i t f il hil th is engaged. • Analytical result is not what was expected © All rights reserved. Do not copy without permission. 5
  • 6. Events P t ti ll I E t Potentially Increasing i Risk No negative q g quality event occurred, but: y • Patient complaints show a negative trend. • Operation drifting/trending towards action i d if i / di d i limit. • Analytical data trending towards unacceptable. © All rights reserved. Do not copy without permission. 6
  • 7. These Events Pose: • Risk to the patient/public • Risk to the product • Risk to the personnel • Risk Ri k to the environement h i • Risk to the company © All rights reserved. Do not copy without permission. 7
  • 8. What Is Risk? The combination of the probability of occurrence of harm and the severity of that harm.* *Guidance for Industry; ICH Q9 Quality Risk Management; June 2006 © All rights reserved. Do not copy without permission. 8
  • 9. What Is The Risk? • In Drug Application: – The pros and cons of the treatment • In Process Design: – Failure to recognize source of variability and how CPP affect CQA of product • In Process Qualification: – Failure to qualify a critical (high risk) portion of the process. • In Manufacturing: – Quality events occurring as the process is engaged © All rights reserved. Do not copy without permission. 9
  • 10. Some Sources of Increased Risk in Manufacturing? • Processing Deviations and Non Conformance • A ti Processing Aseptic P i • Labeling Errors (Majority of drug recalls due to mislabeling) • Analytical and Measuring Errors • D li with potent compounds Dealing ith t t d • People Errors © All rights reserved. Do not copy without permission. 10
  • 11. Defining Level of Risk Function of: F i f – Severity –FFrequency – Detectability • These three factors determine the numerical Risk Priority Number (RPN) • Qualitative risk (low, medium, and high) © All rights reserved. Do not copy without permission. 11
  • 12. CAPA = Corrective Action / Preventive Action © All rights reserved. Do not copy without permission. 12
  • 13. Risk Within the Context of CAPA System y • A non-conformance or deviation occurs or a potential p problem is identified. • These pose risk. • CAPA should define the risk, its level, and means to mitigate it. it • CAPA should then implement the actions to mitigate the risk and track to ensure closure. • M i to ensure action is effective and did not Monitor i i ff i d introduced new risk(s). © All rights reserved. Do not copy without permission. 13
  • 14. Non-conformance and Deviation Non-Conformance: Failure to meet a specified requirement. p q Deviation: Failure to follow or implement an established requirement. Typically this term is used relevant to processes (as in a “process process deviation”). © All rights reserved. Do not copy without permission. 14
  • 15. Risk Level Factors: Severity • What are the consequences of the non-conformance q or deviation? • How deleterious is that non-conformance or deviation to the consistent quality of the product? • How high is the risk to the patient’s well being? © All rights reserved. Do not copy without permission. 15
  • 16. Risk Level Factors: Frequency • What are the probability of the reoccurrence of the non-conformance or deviation? • Were attempts made to reduce such frequency and how effective? • Review process history to determine. © All rights reserved. Do not copy without permission. 16
  • 17. Risk Level Factors: Detectability • What is the probability of the non-conformance or deviation b i d d i i being detected? d? • Can the effect/result of the non-conformance or deviation be dil d i ti b readily measured/seen? d/ ? © All rights reserved. Do not copy without permission. 17
  • 18. Change Control is an Important Component of CAPA © All rights reserved. Do not copy without permission. 18
  • 19. Change Control: A Regulatory Imperative I i • Is a regulatory requirement • 211.68(b) Appropriate controls shall be exercised over computer or related systems to assure that p y changes.... • 211.100 (a) ....written procedures, including any ( ) p , g y changes, shall be drafted, reviewed, and approved by the appropriate organizational units and reviewed and approved by the quality control unit. © All rights reserved. Do not copy without permission. 19
  • 20. • 211 160( ) change in such specifications, 211.160(a) h i h ifi ti standards, sampling plans, test procedures, or other laboratory control mechanisms shall be mechanisms, drafted by the appropriate organizational unit and reviewed and approved by the quality control unit. • Guidance to Industry on Process Validation: The qualification plan for the facility and utilities should identify 1) studies.... 2)Criteria to assess outcome...It should also include the firm's requirements for the evaluation of changes. i t f th l ti f h © All rights reserved. Do not copy without permission. 20
  • 21. • ICH Q7-API GMP (13) A formal change control system should be established to evaluate all changes that could affect the production and control of the intermediate or API. • A proposals f GMP relevant changes should Any l for l h h ld be drafted, reviewed, and approved by the appropriate organizational units and reviewed and approved by the quality unit(s). © All rights reserved. Do not copy without permission. 21
  • 22. What is a Change Control System? It is a formal system which is designed not to prevent change, but rather document and control it. change it Its main purpose is to ensure that a system/process/operation is always in a GMP y p p y compliant and validated state, regardless of changes made to it. It is usually implemented using a procedure. © All rights reserved. Do not copy without permission. 22 22
  • 23. What is a Change Control System? ICH Q9 – Quality Risk Management • T manage changes based on k To h b d knowledge and l d d information accumulated in pharmaceutical development and during manufacturing manufacturing. • To evaluate the impact of the changes on the availability of the final product. © All rights reserved. Do not copy without permission. 23 23
  • 24. What is a Change Control System? • To evaluate the impact on product quality of changes to facility, equipment, material, facility equipment material manufacturing process or conducting technical transfers. • To determine appropriate actions preceding the implementation of a change, e.g., additional testing, (re)qualification, (re)validation, communication with regulators. © All rights reserved. Do not copy without permission. 24 24
  • 25. The Compliance/Validation p Life Cycle - Compliant & Validated System Change Control Implement Change System Modified System © All rights reserved. Do not copy without permission. 25 25
  • 26. Importance of Change Control • Not to prevent change. change • To control and document change. • Required by the regulations. • Identify GMP and validation implications. y p • Ascertain process remains in a state of control. control • Must be implemented using a procedure. © All rights reserved. Do not copy without permission. 26 26
  • 27. Change Control procedure Change required Generate Change Request No GMP Implement Change Implications? Maintenance End Yes Requalification? No Implement Change Issue GMP Obtain Approval Revalidation? & Insure GMP Requirements Done Report Yes Requalify Obtain Change is Revalidate & Change is Issue Reports Approvals Permanent Permanent End © All rights reserved. Do not copy without permission. 27 27
  • 28. CAPA: Mitigating Risk The degree of corrective and preventive action taken to eliminate or minimize actual or potential nonconformities must be appropriate to the magnitude of the p pp p g problem and commensurate with the risks encountered. (ICH Q ) ( Q9) © All rights reserved. Do not copy without permission. 28
  • 29. Risk Level and Appropriate Corrective Action Risk Level (RPN) Low Medium High Corrective Action No Further Investigation , No Corrective action required No Further Investigation (Cause Evident), Corrective action required Further Investigation (Root Cause Analysis), Corrective y ), action required (Immediate; e.g.. Recall), Prevent Cause © All rights reserved. Do not copy without permission. 29
  • 30. What Is CAPA? © All rights reserved. Do not copy without permission. 30
  • 31. CAPA Is: • A quality based system • Uses Non-conformance, Deviations and/or an Expectation of such as input • Uses many of the quality systems in place as tools: – Historical Quality Issues and Audit Reports – Environmental and Process Monitoring Data – Product Complaints – Equipment Service & Maintenance Records – Process and scientific Knowledge – Operating Procedures and Methodology © All rights reserved. Do not copy without permission. 31
  • 32. CAPA Uses: • Policies and procedures to in estigate proced res investigate quality problems. • Policies and procedures to identify and implement corrective and preventive actions. actions • A tracking mechanism to ensure investigation and proper corrective actions are conducted and implemented on a timely basis. © All rights reserved. Do not copy without permission. 32
  • 33. CAPA Investigation • Investigate the cause of non-conformity or deviation as it relates to the product, processes, and the quality system. (reactive) • I Investigate potential risk of an expected or ti t t ti l i k f t d anticipated event. (proactive) • Depending on risk severity the investigation may severity, need to define the “Root Cause.” • Use tools such as HAZOP, HACCP, Failure Mode , , & Effect Analysis, Fault Tree Analysis, What If, etc. © All rights reserved. Do not copy without permission. 33
  • 34. CAPA Identification • Identify the action needed to correct, reduce, or p prevent recurrence of nonconformance of product p and other quality problems. • Identify the action needed to correct and prevent recurrence of the deviation in the process. • Identify the action needed to prevent the potential occurrence of an anticipated quality event. © All rights reserved. Do not copy without permission. 34
  • 35. Possible Corrective Actions • Design Changes* • Manufacturing Process Changes* • Removal of product from the market through recall • Operator Training • Labeling changes* • Patient education ________________________________________________________________________________ * Keep in mind that making changes must be managed using change control in order to avoid introducing additional risk. © All rights reserved. Do not copy without permission. 35
  • 36. Tracking CAPA Activities • What to track? – The quality event and timing for initiating an investigation – Timing for completing assessment – Timing for developing action plan – Timing for implementing all necessary actions (changes, training, document modification, etc.) – Timing for completing the necessary documentation – Completion of the actions and closure of the deviation or nonconformance © All rights reserved. Do not copy without permission. 36
  • 37. Tracking CAPA Activities • How to track? – Manual Tracking • Too much paper • Very cumbersome and time consuming • Limited Access – Software Packages (Part 11 compliant) • Trackwise (MS Outlook) • Livelink (Lotus) © All rights reserved. Do not copy without permission. 37
  • 38. Post CAPA Monitoring • Ensures actions were effective in mitigating the risk. • Ensure actions were effective in correcting/preventive the problem. • Ensures no additional risks were introduced due to the actions taken. • Required as part of GMP compliance and process validation (FDA Guidance 1/2011). © All rights reserved. Do not copy without permission. 38
  • 39. Typical CAPA Overall Approach Quality Event History Identify Risk Risk Ri k Acceptance Document Monitoring Complaints Track& Analyze Risk Risk Reduction Monitor Science & Knowledge Procedures, Service Risk Communicate & Maintenance Evaluate Risk Elimination/ Assign A i RPN prevention Review Risk Assessment/ Identify & Document, Track, Investigate Monitor & Implement Actions l A i Communicate © All rights reserved. Do not copy without permission. 39
  • 40. System Components • D i ti reporting and i Deviation ti d investigation procedure. ti ti d • Rework Procedures. • M i Maintenance records, hi d historical Data, quality audit i lD li di results, etc. • P Process and environmental monitoring programs. d i t l it i • Change Control Procedure. • Ri k Analysis Procedures such as HAZOP, Risk A l i P d h HAZOP HACCP, Fault Tree Analysis, etc. © All rights reserved. Do not copy without permission. 40
  • 41. CAPA Steps to Be Taken © All rights reserved. Do not copy without permission. 41
  • 42. Label and Segregate Non- conforming Product • Ensure nonconforming product is properly labeled (for example, HOLD, REJECT, example HOLD REJECT QUARANTINE). • E Ensure suspect or non-conforming product t f i d t is properly labeled and segregated (not used) t prevent further use pending d) to t f th di disposition. © All rights reserved. Do not copy without permission. 42
  • 43. Document The Issue • Record nonconformance on a Nonconforming Materials Report. g p • Record Deviation on a Deviation Reporting Form. Form • Document all studies and decisions made during the investigation of the quality event. event © All rights reserved. Do not copy without permission. 43
  • 44. Segregate Material & Equipment • A Assure that suspect materials (non-product) i h i l ( d ) is segregated and labeled. • Assure all suspect lots batches units, materials lots, batches, units materials, etc are identified and segregated. • Assure that the segregation (who, what, where, g g ( , , , when, how) is documented on the nonconformance report. • T and lock all equipment and parts of the Tag d l k ll i d f h process which maybe suspect. © All rights reserved. Do not copy without permission. 44
  • 45. Evaluate • Review the event, the circumstances surrounding the event. • Document relevant details as part of the nonconformance or deviation report. report • Risk to quality should be linked to protecting the patient. • Use RPN to help determine need for in-depth investigation and Corrective/Preventive Action (in other words: the effort, formality and documentation should be commensurate with the level of risk and be based on science*). __________________________________________________________________________ *Guidance for Industry; ICH Q9 Quality Risk Management; June 2006 © All rights reserved. Do not copy without permission. 45
  • 46. Risk Level and Appropriate Corrective Action Risk Level (RPN) Low Medium High Corrective Action Further Investigation (Root Cause Analysis), Corrective action required (Immediate; e.g.. Re ll) P e e t C e e Recall), Prevent Cause No Further Investigation (Cause Evident), Corrective action required No Further Investigation , No Corrective action required © All rights reserved. Do not copy without permission. 46
  • 47. Take Action • M k necessary changes to reduce risk or Make h d ik eliminate it. • Invoke Change Control. Control • Track to ensure CAPA closure in a timely fashion. • Evaluate the actions to ensure they were effective in mitigating the risk as intended. • Monitor the process to ensure it has not been p negatively affected by changes and that no additional or different risks were introduced. © All rights reserved. Do not copy without permission. 47
  • 48. Benefits of a Robust CAPA System • Fulfills the promise of continuous improvement • Leads to better customer satisfaction and less risk to the public. h bli • Better use of resources through a structured QA system. system • Facilitate better and more informed decisions by manufacturers. • Makes good business and financial sense. • Increasing your compliance q gy p quotient. © All rights reserved. Do not copy without permission. 48
  • 49. Summary y • CAPA is a regulatory requirement which makes business sense. • CAPA is a risk mitigating approach, which fulfills the promise of continuous improvement improvement. • Non-conformances, deviations or anticipated quality events are input to the CAPA program. • All aspects of the CAPA program should be thoroughly documented. • Risk level assessment, as part of CAPA: p provides the means for rationalizing the scope and g p extent of investigation and/or corrective action necessary. helps management assign resources to tasks providing the most value and having the biggest impact on al e ha ing quality and customer satisfaction. • Tracking, reviewing, and monitoring CAPA related activities is an important aspect of the program. © All rights reserved. Do not copy without permission. 49